

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Hansoh Pharmaceutical Group Company Limited

翰森製藥集團有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 3692)

VOLUNTARY ANNOUNCEMENT

COLLABORATION AGREEMENT WITH ANTENGENE

The board of directors (the “**Board**”) of Hansoh Pharmaceutical Group Company Limited (the “**Company**”) and together with its subsidiaries, the “**Group**”) is pleased to announce that on August 10, 2023, Jiangsu Hansoh Pharmaceutical Group Company Limited* (江蘇豪森藥業集團有限公司), a wholly-owned subsidiary of the Company, entered into an exclusive collaboration agreement (the “**Collaboration Agreement**”) with Antengene Corporation (Hong Kong) Limited and Antengene (Zhejiang) Pharmaceutical Technology Company Limited* (德琪(浙江)醫藥科技有限公司), both subsidiaries of Antengene Corporation Limited (collectively, “**Antengene**”).

Pursuant to the Collaboration Agreement, the Group will be exclusively responsible for commercialization of selinexor and any product containing or comprising of selinexor (marketed as XPOVIO®) in the mainland of China and Antengene will continue to be responsible for research and development, regulatory approvals and affairs, product supply, and distribution of XPOVIO® (selinexor). Antengene will receive up to RMB200 million of upfront payments, RMB100 million of which shall be received upon signing and pursuant to the Agreement and subject to the terms and conditions thereof, Antengene shall be eligible to receive up to RMB100 million of the remaining upfront payments, and up to RMB535 million in milestone payments. The Group will receive a service fee from Antengene.

ABOUT XPOVIO® (SELINEXOR)

XPOVIO® (selinexor) is the world’s first orally-available, selective inhibitor of the nuclear export protein XPO1 being developed for the treatment of various hematological malignancies and solid tumors. As at the date of this announcement, XPOVIO® (selinexor) is approved in the mainland of China for the indication which in combination with dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma who have received prior therapies and whose disease is refractory to at least one proteasome inhibitor, at least one immunomodulatory agent, and an anti-CD38 monoclonal antibody.

ABOUT ANTENGENE

Antengene, a company listed on The Stock Exchange of Hong Kong Limited with stock code: 6996, is a biopharmaceutical company focused on the discovery, development, manufacturing and commercialization of the treatment of hematologic malignancies and solid tumors. To the best knowledge and belief of the Company, Antengene is independent of, and is not connected with, the Company and its connected person (as defined in the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”). The transactions contemplated under the Collaboration Agreement do not constitute any notifiable transactions or connected transactions of the Company under Listing Rules.

By Order of the Board
Hansoh Pharmaceutical Group Company Limited
Zhong Huijuan
Chairlady

Hong Kong, August 11, 2023

As at the date of this announcement, the Board comprises Ms. Zhong Huijuan as chairlady and executive director, Mr. Lyu Aifeng and Ms. Sun Yuan as executive directors, and Mr. Lin Guoqiang, Mr. Chan Charles Sheung Wai and Ms. Yang Dongtao as independent non-executive directors.

* *For identification purposes only*